Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ET 190

Drug Profile

ET 190

Alternative Names: ET-190; ET190L1-AbTCR T-cells - Eureka Therapeutics; ET190L1-ARTEMIS™; ET190L1-ARTEMIS™ T cells

Latest Information Update: 05 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eureka Therapeutics
  • Developer Duke University; Eureka Therapeutics; First Affiliated Hospital-Xi'an Jiaotong University
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B-cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Jan 2019 Eureka Therapeutics terminates phase I trial in Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV) (NCT03379493)
  • 01 Dec 2018 Interim efficacy and adverse events data from the phase I trial in B-cell lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
  • 04 Jun 2018 Eureka Therapeutics plans a phase I trial for Precursor B-cell lymphoblastic leukaemia-lymphoma (In adults, In children, In adolescents, Second-line therapy or greater) in USA (IV) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top